医療機器リーダーシリーズ：世界の無針注射器開発、製造および販売におけるトップ企業2016...市場調査レポートについてご紹介

1. Report Overview
1.1 Overview of the Top Needle-Free Injection Device Manufacturers
1.2 Why You Should Read This Report
1.3 How This Report Delivers Research and Analysis
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to Needle-Free Injection
2.1 What is Needle-Free Drug Delivery?
2.1.1 History of Needle-Free Injections: From Military to Clinic
2.1.2 Modern Needle-Free Devices: Concept of High Pressure Fluid Jet
2.2 What is the Rationale for Needle-Free Injections?
2.3 Applications of Needle-Free Drug Delivery
2.3.1 Pain Management: Using NFI Devices to Administer Lidocaine
2.3.2 Vaccine Delivery: Improving Immune Response
2.3.3 Insulin Delivery: Jet Injection Enhances Drug Distribution
2.3.4 Paediatrics: Alleviating Childhood Anxiety and Phobia
2.4 Regulation of Needle-Free Delivery Devices
2.4.1 The US Regulation System: Prolonged Approval Process
2.4.2 The European Regulation System: Manufacturers Seeking EU Approval First?
2.5 Advantages and Disadvantages of Needle-Free Systems

3. The Global Needle-Free Injection Devices Market, 2016-2026
3.1 The Global Needle-Free Injection Device Market, 2016
3.2 The Global Needle-Free Injection Device Market: Revenue Forecast, 2016-2026
3.3 What Will Drive The Global Needle-Free Injection Device Market Between 2016 and 2026?
3.4 What Factors are Likely to Restrain the Global Needle-Free Injection Device Market Between 2016 and 2026?
3.5 The Global Jet Injector Device Market, 2016
3.5.1 The Global Jet Injector Device Market: Industry Trends, 2016-2026
3.6 The Global Competing Technologies Market, 2016
3.6.1 The Global Competing Technologies Market: Industry Trends, 2016-2026
3.6.1.1 Transdermal Patches: Attractive and Cheap Option
3.6.1.2 Microneedle Technology: Huge Potential for Mass Vaccinations
3.6.1.3 Metered Dose Inhalers: Change in Device Propellant to Drive Adoption
3.7 Needle-Free Delivery Technology: Market Trends, 2016-2026
3.8 Needle-Free Delivery Technology: Drivers and Restraints, 2016-2026

4. Leading North American Needle-Free Injection Device Manufacturers, 2016
4.1 Antares Pharma
4.1.1 Antares Pharma: Financial Overview
4.1.2 Needle-Free Products
4.1.2.1 ZOMAJET™: Delivering Liquid Insulin or Human Growth Hormone
4.1.2.2 Vibex™: Hidden Needle to Alleviate Patient Fear
4.1.2.3 OTREXUP™: Combining Vibex MTX and Methotrexate
4.1.2.4 Vibex™ MTX: Targeting Growing Population of RA Sufferers
4.1.2.5 T-JET™
4.1.3 Needle-Free Injection Device Pipeline
4.1.3.1 Vibex™ QS (QuickShot): Modified Vibex to Offer Improved Function
4.1.3.2 Pen Injector: Devices Being Used Clinical Testing
4.1.3.3 VIBEX® QS T
4.1.3.4 VIBEX® QS M
4.2 Mylan Inc.
4.2.1 Mylan: Financial Overview
4.2.2 Needle-Free Products
4.2.2.1 EpiPen® Auto-Injector
4.2.2.2 EpiPen Jr® Auto-Injector
4.3 Bioject Medical Technologies
4.3.1 Bioject Medical Technologies: Financial Overview
4.3.2 Needle-Free Products
4.3.2.1 Biojector® 2000: Adaptable Power Source Allows Use in Home and Mass Vaccination Setting
4.3.2.2 Vitajet™: Low-Cost Insulin Delivery System
4.3.2.3 Bioject® ZetaJet™: Auto-Disable Feature Improves User Safety
4.3.2.4 Bioject® Drug Reconstitution System
4.3.2.5 Bioject® Needle-Free Vial Adapter
4.3.3 Needle-Free Injection Device Pipeline
4.3.3.1 Intradermal Pen Injector: Targeted Drug Delivery
4.3.3.2 Iject®: Providing Tailored Depth of Penetration
4.3.3.3 Iject® R: The Reusable Version
4.3.3.4 Jupiter Jet: Multi Dosing With Single Loaded Syringe
4.3.3.5 Mega Jet: The New Design
4.3.4 Collaborations
4.3.4.1 MPI Research: Seeking Drug/Device Combinations
4.3.4.2 World Health Organisation (WHO): The Push to Eradicate Infectious Disease in Developing Countries
4.4 Activa Brand Products, Inc.
4.4.1 Technology: The Activa Family for Diabetics
4.4.2 Needle-Free Products
4.4.2.1 Product Advantages
4.5 D’Antonio Consultants International Inc. (DCI)
4.5.1 Needle-Free Products
4.5.1.1 LectraJet®: Lightweight Device Reduces User Fatigue
4.5.2 Needle-Free Injection Device Pipeline
4.5.2.1 Low Workload Jet Injector: Single-Shot Manuel System
4.5.2.2 Multi-Channel Jet Injector: For Simultaneous Vaccine Delivery
4.6 National Medical Products, Inc.
4.6.1 Needle-Free Products
4.6.1.1 J-Tip®: Offering Needle-Free Administration of Anaesthesia
4.7 Medical International Technologies
4.7.1 Needle-Free Products
4.7.1.1 MED-JET®: Extremely Thin Orifice Offers Improved Drug Absorption
4.7.2 Increased Awareness Through Globalisation
4.8 Penjet Corporation
4.8.1 Needle-Free Products
4.8.1.1 Penjet®: Nitrogen-Powered Device Allows Efficient Storage
4.8.2 Applications
4.8.2.1 Multi-Component Drugs
4.8.2.2 Lyophilised Drug Delivery
4.8.2.3 Small Pox Vaccination
4.9 PharmaJet
4.9.1 Needle-Free Products
4.9.1.1 STRATIS®: Drug Delivery in Less Than a Second
4.9.2 Applications
4.9.3 Collaborations: Pursuing a Drug/Device Combination for Vaccine Administration
4.10 Valeritas
4.10.1 Needle-Free Products
4.10.1.1 Mini-Ject™: Potential Delivery of Lyophilised Drugs May Open Huge Opportunities for Valeritas
4.10.1.2 V-Go®: Click and Go Technology to Simplify Insulin Drug Delivery
4.10.1.3 Micro-Trans™:
4.10.1.4 h-Patch™: Controlled Delivery Patch
4.11 3M (MMM)
4.11.1 Needle-Free Products
4.11.1.1 3M: Metered Dose Inhaler
4.11.1.2 3M: Transdermal Patch
4.11.1.3 3M: Microneedle
4.12 Zogenix
4.12.1 Needle-Free Products
4.12.2 Needle-Free Injection Pipeline
4.13 BD – Becton, Dickinson and Company
4.13.1 Needle-Free Products
4.13.1.1 BD SmartSite
4.13.1.2 Soluvia
4.13.1.3 BD Ultra-Fine Nano Pen Needle
4.13.1.4 AutoShield Duo Pen Needle (BD)
4.13.1.5 BD Accuspray SCF Nasal Spray System
4.14 Portal Instruments
4.14.1 Needle-Free Products
4.14.1.1 Portal’s Needle-Free Jet Injector
4.14.1.2 Partnering

5. Leading European Needle-Free Injection Device Manufacturers, 2016
5.1 Akra Dermojet
5.1.1 Needle-Free Products
5.1.1.1 Dermojet® “HR”: User-Friendly Design Allows Use in High Intensive Applications
5.1.1.2 DERMOJET Polymedical®: Interchangeable Injection Tips Reduces Risk of Contamination
5.1.1.3 Automatic DERMOJET®
5.2 Crossject Medical Technology
5.2.1 Technology: Highly Customisable Device Allows Tailoring to Specific Drugs
5.2.2 Needle-Free Products
5.2.2.1 Zeneo®: Gas Propellant Generated Upon Injection
5.3 Glide Pharma
5.3.1 Needle-Free Products
5.3.1.1 Glide SDI®
5.3.1.2 Applications
5.3.2 Advantages
5.3.2.1 Injecting Solid Formulations
5.3.2.2 Pharmaceutical Companies
5.3.3 Collaboration With Pfenex Inc. to Aid Delivery of Solid Dose Vaccine
5.4 Merck KGaA
5.4.1 Needle-Free Products
5.4.1.1 Cool.click® and Cool.click2®
5.4.1.2 Click.easy®
5.4.1.3 SeroJet™
5.5 Spirit Healthcare
5.5.1 Spirit Healthcare Needle-Free Products
5.5.1.1 InsuJet™
5.6 AstraZeneca
5.6.1 AstraZeneca’s Needle-Free Product

6. Leading Emerging-Market Needle-Free Device Manufacturers, 2016
6.1 Injex Pharma AG
6.1.1 Needle-Free Products
6.1.1.1 INJEX30®: First Multiple Application Needle-Free Device?
6.2 Romsons Scientific & Surgical Pvt. Ltd.
6.2.1 Needle-Free Products
6.2.1.1 Safesite™
6.2.1.2 Exteena™ Uno
6.2.1.3 Exteena™ Duo
6.2.1.4 Exteena™ Trio
6.3 Binny’s Health Care Ltd
6.3.1 Needle-Free Products
6.3.1.1 Binny’s Needle-Free IV Injection

7. Leading Needle-Free Injection Companies in the Rest of the World, 2016
7.1 Mika Medical Co.
7.1.1 Needle-Free Products
7.1.1.1 Comfort-in™
7.2 JMS Singapore Pte Ltd
7.2.1 Needle-Free Products
7.2.1.1 Planecta™
7.3 B. Braun Singapore Pte Ltd.
7.3.1 Needle-Free Products
7.3.1.1 CARESITE® Luer Access Device (LAD)
7.3.1.2 SAFELINE® Split Septum Needleless Connector
7.3.1.3 ULTRASITE® Luer Access Device
7.4 NanoPass Technologies
7.4.1 Nanopass Drug Delivery Products
7.4.1.1 Micronjet Needle
7.4.1.2 Anti-Aging Microdermabrasion
7.5 Vaxxas
7.5.1 Needle-Free Products
7.5.1.1 The Nanopatch™

8. Qualitative Analysis of the Global Needle-Free Injection Device Market, 2016-2026
8.1 SWOT Analysis of the Global Needle-Free Injection Device Market, 2016-2026
8.1.1 Strengths
8.1.1.1 A Less Painful Alternative to Needle-Based Injections
8.1.1.2 No Specialist Training Required for Delivery
8.1.1.3 Strong Growth in the Biologic Drug Market
8.1.1.4 Increasing Development in Transdermal Delivery
8.1.1.5 Reduced Transport Costs and Eliminating the Cold Chain Problem
8.1.2 Weaknesses
8.1.2.1 Expensive Technology
8.1.3 Healthcare Practitioners Are Not Familiar with Novel Delivery Systems
8.1.3.1 Inefficient Manufacturing Process
8.1.4 Greater Regulatory Scrutiny
8.1.4.1 Off Patent/Generics Require Reformulating Prior to Use in Needle-Free Delivery Systems
8.1.5 Opportunities
8.1.5.1 Emerging Economies
8.1.5.2 Mass Immunisation Programmes
8.1.5.3 Shift Towards Home Administration Setting
8.1.5.4 Potential Delivery of Vaccines
8.1.5.5 Increasing Global Diabetes Population
8.1.5.6 Extending Life Cycle of Drugs
8.1.6 Threats
8.1.6.1 Traditional Needles and Syringes are Cheap to Mass Produce
8.1.6.2 Limited Clinical Data
8.1.6.3 Increased Scrutiny from Regulatory Bodies
8.1.6.4 Needle and Syringes with Anti Needlestick Injury Technology
8.2 STEP Analysis of the Global Needle-Free Injection Device Market, 2016-2026
8.2.1 Social Factors
8.2.2 Technological Developments
8.2.3 Economic Pressures
8.2.4 Political Issues

9. Research Interview
9.1 Mr David Hoey, CEO, Vaxxas
9.1.1 Vaxxas Overview
9.1.2 Introducing the Nanopatch™
9.1.3 Vaxxas’ Leading Strategy: Competition & Collaboration
9.1.4 Future Directions for Vaxxas and the Industry

10. Conclusions
10.1 The Global Needle-Free Injection Device Market, 2015-2026
10.2 Antares Pharma Dominates the Global Needle-Free Injection Device Market in 2016
10.3 Strong Pipeline Will Drive the Competing Needle-Free Injection Technology Market
10.4 The Future of the Needle-Free Technology Market?
10.5 Biosimilars are a Major Driver of the Needle Free Drug Delivery Market
10.6 Concluding Remarks